Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2020-11-05 Interim / Quarterly Rep…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Q3 verslag 2020.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Derde kwartaalverslag 2020' (Third Quarter Report 2020) for Galapagos. It contains detailed financial statements, management discussion and analysis (MDA), operational highlights, and an auditor's report for the interim period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2020
2020-11-05 Dutch
EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF ULCERATIVE COLITIS
Regulatory Filings Classification · 95% confidence The document is a press release dated November 2, 2020, announcing that the European Medicines Agency (EMA) has validated and is now evaluating the marketing authorization application for filgotinib for the treatment of ulcerative colitis (CU). It details the supporting clinical trial data (SELECTION study) and includes standard forward-looking statements and contact information typical of corporate announcements. This type of announcement, which communicates a significant regulatory milestone (validation/evaluation of an application) but is not the final approval or a comprehensive financial report, most closely aligns with a general regulatory announcement or a specific type of corporate news release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A), and it is a formal communication about a regulatory process, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a specific regulatory update that doesn't fit the other specialized codes. It is too detailed and substantive to be a simple Report Publication Announcement (RPA).
2020-11-03 English
EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF ULCERATIVE COLITIS
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the European Medicines Agency (EMA) has validated a marketing application for the drug filgotinib for ulcerative colitis treatment. It details the supporting clinical trial data (SELECTION trial) and includes standard forward-looking statements and contact information typical of corporate news releases regarding product development milestones. This type of announcement, focusing on regulatory progress and clinical data summaries, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific regulatory/clinical update that doesn't fit other categories like M&A (TAR) or Capital Change (CAP), it functions as a general corporate announcement. Given the options, it is a significant corporate event announcement. It is not a full financial report (10-K, IR), a transcript (CT), or a presentation (IP). It is a high-level announcement of a regulatory step. In the context of financial filings, press releases announcing major regulatory milestones often fall under the general 'Regulatory Filings' (RNS) category if they don't fit a more specific category like ER or LTR. However, since it is a major announcement of a regulatory validation, and it is not a report itself (satisfying the 'MENU VS MEAL' rule), it is a general corporate announcement. Given the available codes, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate fit for a press release detailing regulatory progress that isn't explicitly an earnings release or a legal proceeding update.
2020-11-03 English
6-K Filing
Regulatory Filings
2020-11-03 English
Galapagos’ R&D Roundtable showcases Toledo program
Regulatory Filings Classification · 93% confidence The document is a press release dated October 27, 2020, detailing scientific updates, preclinical data, and ongoing clinical trial progress (Phase 1 and Phase 2 studies) for a drug candidate (GLPG3970) within the Toledo program. It highlights key scientific findings and outlines the development strategy. This content structure—announcing scientific progress, clinical trial updates, and future plans via a formal release—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/pipeline news. Since it focuses on R&D progress and clinical pipeline status rather than summarizing overall quarterly financial performance (which would be an ER or IR), and it is not a transcript (CT), investor presentation (IP), or a formal regulatory filing like a 10-K, the most fitting category for a major, non-financial results-focused announcement of this nature is often the Earnings Release category if it accompanies period results, or a general Regulatory Filing (RNS) if it's purely scientific. However, given the depth of clinical trial updates and scientific disclosure, it strongly resembles an announcement accompanying or preceding financial results, or a standalone pipeline update. Since it is a formal announcement of scientific and clinical milestones, and not a full report, it fits best as an Earnings Release (ER) if it's tied to a reporting period, or RNS if it's purely informational. Given the date and the nature of pipeline updates, it functions as a significant corporate announcement. In the absence of explicit quarterly financial figures, and focusing purely on the scientific/clinical update, it is a major corporate disclosure. If this were a standalone announcement not tied to quarterly results, RNS would be appropriate. However, many companies issue these detailed pipeline updates around earnings time. Since it is a formal press release detailing significant operational/pipeline progress, and it is not a specific report type, I will classify it as an Earnings Release (ER) as these often contain significant non-financial operational updates, or RNS as a general regulatory announcement. Given the structure, it reads like a detailed corporate update, which often falls under ER if it's timely, or RNS if it's purely informational. I will lean towards RNS as the most neutral fit for a detailed scientific/clinical update that isn't explicitly a financial summary or presentation.
2020-10-28 English
Galapagos’ R&D Roundtable showcases Toledo program
Earnings Release Classification · 95% confidence The document is a press release dated October 27, 2020, detailing scientific updates, preclinical data, and ongoing Phase 1/2 clinical trials (CALOSOMA, SEA TURTLE, LADYBUG) for a drug candidate (GLPG3970) related to the 'Toledo program'. It announces key results and outlines the future development plan, including recruitment status for patient studies. This content structure—announcing scientific progress, clinical trial updates, and future outlook in a formal press release format—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses heavily on R&D progress and clinical pipeline updates rather than summarizing overall quarterly financial performance (which would typically be an ER), and it is not a full regulatory report (like 10-K or IR), it best fits the category for initial financial/operational highlights or announcements. Given the focus on announcing new data and clinical progress, 'Earnings Release' (ER) is the most appropriate fit among the options for a major operational update, even if it's not strictly tied to a quarterly earnings report date. It is a formal announcement of significant operational/scientific milestones. FY 2020
2020-10-28 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.